Literature DB >> 1912034

High-dose IgG for neutropenic patients with acquired immunodeficiency syndrome (AIDS).

A Salama1, J Lohmeyer, W Seeger, C Mueller-Eckhardt.   

Abstract

Leukocytopenia and bacterial infections are common and serious complications in patients with AIDS. We report here on three patients in whom the administration of high IgG doses led to gradual (two patients) or prompt (one patient) increases in circulating leukocyte counts (from 200-600 to 2500-5900/microliters), inducing definite improvement in two patients; one patient died from Pneumocystis carinii pneumonia. Although the rise in leukocyte counts lasted for only approximately 3 weeks, high-dose IgG might be a useful therapeutic adjunct in such patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912034     DOI: 10.1007/bf01707276

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  4 in total

Review 1.  Pathophysiology and management of HIV-associated hematologic disorders.

Authors:  D T Scadden; L I Zon; J E Groopman
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

Review 2.  Intravenous immunoglobulin for secondary immunodeficiency.

Authors:  P L Yap
Journal:  Blut       Date:  1990-01

3.  Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection.

Authors:  M F Murphy; P Metcalfe; A H Waters; C A Carne; I V Weller; D C Linch; A Smith
Journal:  Br J Haematol       Date:  1987-07       Impact factor: 6.998

4.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

  4 in total
  1 in total

Review 1.  Does intravenous immune globulin have a role in HIV-infected patients?

Authors:  P L Yap
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.